Detalhe da pesquisa
1.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31943171
2.
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Breast Cancer Res
; 22(1): 83, 2020 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758299
3.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31330065
4.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
J Cell Physiol
; 233(3): 2313-2323, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28710865
5.
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
J Cell Physiol
; 232(6): 1571-1578, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27861874
6.
Symptom improvement as prognostic factor for survival in cancer patients undergoing palliative care: a pilot study.
Support Care Cancer
; 20(6): 1221-6, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21688165
7.
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.
J Natl Cancer Inst
; 114(3): 400-408, 2022 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34850043
8.
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
JAMA
; 306(3): 269-76, 2011 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-21771987
9.
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Breast J
; 16(1): 66-72, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19889170
10.
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Cancer Biol Ther
; 20(2): 192-200, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403909
11.
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Cancer Biol Ther
; 19(4): 328-334, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29336662
12.
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Oncotarget
; 8(34): 56921-56931, 2017 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28915642
13.
Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
Anticancer Res
; 22(5): 3053-6, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12530041
14.
[ECCO 2005. Advances in the prevention of chemotherapy-induced nausea and vomiting]. / ECCO 2005. Progressi nella prevenzione della nausea e del vomito da chemioterapia.
Tumori
; 92(1): suppl 24-31, 2006.
Artigo
em Italiano
| MEDLINE | ID: mdl-16683393